IDH2 and myelodysplastic syndrome: Preliminary results were presented on the first 16 treated patients with IDH2-mutated AML and myelodysplastic syndrome (MDS) who initiated enasidenib maintenance therapy 30 to 90 days after allo-HCT for up to twelve 28-day cycles.